Clinical Trials Browser

Phase 2 × Active not recruiting × Prostatic Neoplasms × Clear all

NCT03181867 2026-04-22

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03436654 2026-04-22

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04530552 2026-04-22

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Phase 2 Active not recruiting

34 enrolled 11 charts

Prostatic Neoplasms

NCT07047118 2026-04-21

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 2 Active not recruiting

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT00951535 2026-04-17

A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03821792 2026-04-15

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05828082 2026-04-14

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05960578 2026-04-14

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02893917 2026-04-13

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Phase 2 Active not recruiting

90 enrolled 19 charts

Prostatic Neoplasms

NCT04842890 2026-04-13

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05849298 2026-04-13

PSMACare

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00859781 2026-04-08

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Phase 2 Active not recruiting

55 enrolled 11 charts

Prostatic Neoplasms

NCT05053152 2026-04-08

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03173924 2026-04-06

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Phase 2 Active not recruiting

Disease, Prostatic Neoplasms

NCT03976843 2026-04-06

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04709276 2026-04-06

CHAMP

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05059236 2026-04-02

ARASEC

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03419234 2026-04-01

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Phase 2 Active not recruiting

223 enrolled 14 charts

Prostatic Neoplasms

NCT04300855 2026-04-01

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05114746 2026-04-01

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT01251861 2026-03-31

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Phase 2 Active not recruiting

108 enrolled 16 charts

Prostatic Neoplasms

NCT03471650 2026-03-30

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06395753 2026-03-30

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04663997 2026-03-27

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05826509 2026-03-27

SUGAR

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03787680 2026-03-23

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Phase 2 Active not recruiting

49 enrolled 11 charts

Prostatic Neoplasms

NCT04597359 2026-03-23

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04879940 2026-03-23

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Phase 2 Active not recruiting

Prostatic Hyperplasia, Prostatic Neoplasms

NCT03412396 2026-03-19

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Phase 2 Active not recruiting

45 enrolled 10 charts

Prostatic Neoplasms

NCT04190446 2026-03-16

A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00525720 2026-03-09

Brachytherapy for Prostatic Carcinoma Patients

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02905318 2026-03-09

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03808077 2026-03-09

The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer

Phase 2 Active not recruiting

139 enrolled 9 charts

Muscle Hypotonia, Prostatic Neoplasms

NCT06463457 2026-03-09

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04104893 2026-02-27

CHOMP

Phase 2 Active not recruiting

Turcot syndrome, Prostatic Neoplasms

NCT04422132 2026-02-27

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT01410942 2026-02-20

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

Phase 2 Active not recruiting

Fatigue, Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04751929 2026-02-20

Abemaciclib With or Without Atezolizumab for mCRPC

Phase 2 Active not recruiting

19 enrolled 13 charts

Prostatic Neoplasms

NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Phase 2 Active not recruiting

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

NCT04558866 2026-02-12

ExBAT

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05320406 2026-02-12

REVELUTION

Phase 2 Active not recruiting

94 enrolled 13 charts

Prostatic Neoplasms

NCT03624660 2026-02-10

PR11

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05751434 2026-02-06

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03902951 2026-02-05

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms